West Pharmaceutical Services (NYSE:WST) has expanded its analytical services capabilities with new equipment to help address the pharmaceutical industry’s packaging and drug-delivery concerns, the company said today.
West specifically highlighted its addition of an ion mobility quadrupole time-of-flight mass spectrometer – an instrument that combines chromatography, ion mobility and mass spectrometry.
The company also added a new oxygen headspace analyzer to run deterministic container closure integrity analyses on packaging and delivery systems.
“To ensure that therapies are coming to market safely and effectively, it’s critical that our customers have the needed data and insights to thoroughly examine the compatibility between a therapy and its primary containment and delivery technology to mitigate potential risk to patients and help them move more easily through development,” Jennifer Riter, senior director of analytical services at West, said in prepared remarks.
“Customers can mitigate risk by combining these enhanced capabilities with West’s analytical services expertise and experience in extractables and leachables, particle analysis, CCI, and packaging and delivery system performance, among other methodologies,” Riter added. “In addition, West’s deep understanding of materials and delivery systems combined with the ability to analyze drug product compatibility enables the ability for a unique partnership from early development throughout lifecycle management.”